Free Trial

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Logo sign of Pharmaceutical Corporation Pfizer building

Key Points

  • Pharmaceutical giant Pfizer is experiencing normalization of COVID-related revenues as non-COVID revenues grew 11% YoY in Q1 2024.
  • Pfizer’s CEO revealed it has three weight-loss drugs in the works to challenge Wegovy and Zepbound GLP-1 drugs.
  • Pfizer's weight loss treatments are comprised of 2 GLP-1 drugs and 1 non-GLP-1 drug.
  • 5 stocks we like better than Pfizer.

Pfizer Today

Pfizer Inc. stock logo
PFEPFE 90-day performance
Pfizer
$26.36 +0.59 (+2.29%)
(As of 12/20/2024 05:45 PM ET)
52-Week Range
$24.48
$31.54
Dividend Yield
6.53%
P/E Ratio
35.62
Price Target
$32.14

Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender. 

Pfizer operates in the medical sector. In addition to the incumbents Novo Nordisk and Eli Lilly, it competes with other GLP-1 developers, including Viking Therapeutics Inc. NASDAQ: VKTX, Altimmune Inc. NASDAQ: ALT and Structure Therapeutics NASDAQ: GPCR.

Pfizer Halts Lotiglipron Trials Due to Liver Toxicity Concerns

Pfizer had two promising GLP-1 drugs. However, it ended clinical trials in June 2023 for its second obesity and Type 2 diabetes mellitus treatment, lotiglipron. Lotiglipron was an oral GLP-1-RA contender with a once-a-day treatment that was seen as a viable contender to Ozempic. However, Phase 1 and Phase 2 clinical trial data indicated elevated transaminase enzyme levels, indicating the potential for liver dysfunction. To be clear, none of the enrolled participants reported liver-related side effects, symptoms, or liver failure.

Pfizer Discontinues Danuglipron Trials Due to High Dropout Rates

The company decided to continue forward with its twice-a-day formulation of danuglipron. However, on Dec. 1, 2023, Pfizer discontinued its mid-stage trials of danuglipron due to dropouts driven by high rates of side effects, including vomiting and nausea. Nearly half the patients dropped out at certain dosages due to harsh gastrointestinal side effects. The drug enabled 13% weight loss in week 32, which rivals Eli Lilly's oral drug, which hit 15% in week 36.

Pfizer CEO Hints at 3 Weight-Loss Drugs

During a Semafor event interview on June 24, 2024, Pfizer CEO Alfred Bourla noted that Pfizer is currently working on three weight-loss treatments. Pfizer decided to proceed with a new formulation of danuglipron that would be used once a day as a pill. The company will provide trial data for the once-a-day version of danuglipron in 2024.

Bourla didn't provide much more details, except that the company has two GLP-1 technology drugs and one non-GLP-1 mechanism in the works. The company is determined to get a piece of the medical weight-loss treatment segment.

PFE Stock Continues to Chop in a Descending Triangle Pattern

The daily candlestick chart for PFE indicates a descending triangle pattern. The news of Pfizer testing three weight-loss drug candidates peaked out its second attempt to break out of the triangle range at $28.45, as shares again fell to retest the flat-bottom lower trendline at $27.07. The descending trendline started at the $29.73 swing high on June 4, 2024, as shares tested the flat-bottom lower trendline four times thereafter. A third test of the descending trendline is underway at $28.12. The daily relative strength index (RSI) illustrates a bounce attempt at the 50-band. Pullback support levels are at $27.07, $26.52, $25.61, and $24.50.

Pfizer's Recovery from COVID-19 Revenue Decline: Q1 Performance and Future Outlook

Pfizer MarketRank™ Stock Analysis

Overall MarketRank™
99th Percentile
Analyst Rating
Hold
Upside/Downside
21.9% Upside
Short Interest Level
Healthy
Dividend Strength
Strong
Environmental Score
-2.64
News Sentiment
0.44mentions of Pfizer in the last 14 days
Insider Trading
Acquiring Shares
Proj. Earnings Growth
-1.69%
See Full Analysis

Pfizer has been experiencing a steep decline in COVID-19-related revenues. The decline has been the primary driver of its falling revenues. Its Q1 2024 EPS was 82 cents, beating consensus EPS estimates by 31 cents. Revenues continued to fall 19.5% YoY to $14.88 billion, still beating the consensus estimates of $13.87 billion. The expected decline of its COVID-19 drugs Comirnaty and Paxlovid revenues were the key drivers for the fall. Non-COVID revenues climbed 11% YoY. The company is trying to recover from the normalization of COVID-19 revenues as it becomes more routine, like the flu shot.

Despite the revenue decline, Pfizer is on track to deliver at least $4 billion in net cost savings for 2024. The company reaffirmed its full-year 2024 revenue guidance of $58.5 billion to $61.5 billion and raised its adjusted diluted EPS guidance to $2.15 to $2.35, up from previous estimates of $2.05 to $2.25 versus $2.21 consensus estimates.

Pfizer CEO is Upbeat About Non-COVID-Related Performance

CEO Bourla was bullish on the company's non-COVID performance in Q1 2024. The company increased revenue from several commercial launches and acquired products from its Seagen acquisition. Robust YoY growth occurred for several of its key in-line brands, including the Eliquis, Prevnar, and Vyndaqel family of medicines. Oncology revenue contributions were strong from Xtandi, Padcev, Adcetris, and Ibrance.

Dr. Bourla concluded, “Overall, I am encouraged by a well-executed quarter, setting the tone for the year. Pfizer’s commercial leadership is focused on data-driven opportunities across several key growth brands, both in the U.S. and internationally, and we intend to build on this positive momentum in the quarters ahead.”

Pfizer analyst ratings and price targets are at MarketBeat. The consensus analyst price target of $35.86 implies a 28.15% upside.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Trading Strategies

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9681 of 5 stars
$26.36+2.3%6.53%35.62Hold$32.14
Novo Nordisk A/S (NVO)
3.7264 of 5 stars
$85.00-17.8%0.85%27.51Buy$150.40
Eli Lilly and Company (LLY)
4.9955 of 5 stars
$767.76+1.3%0.78%83.00Moderate Buy$1,002.22
Viking Therapeutics (VKTX)
4.2944 of 5 stars
$42.25+1.8%N/A-45.43Buy$106.75
Altimmune (ALT)
1.7723 of 5 stars
$8.25+0.9%N/A-5.32Moderate Buy$20.00
Structure Therapeutics (GPCR)
2.1976 of 5 stars
$27.90-6.9%N/A-37.70Buy$86.50
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines